Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Dosage Regimen: Fixed Dose

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...

Cholinergic Antagonists: Pharmacokinetics

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effectiveness and safety of early lens extraction during par plana vitrectomy for proliferative diabetes retinopathy with mild cataract: a randomized clinical trial.

International journal of ophthalmology·2024

Same author

Use of a tissue clearing technique combined with retrograde trans-synaptic viral tracing to evaluate changes in mouse retinorecipient brain regions following optic nerve crush.

Neural regeneration research·2022

Same author

Neuroprotective Effects of Ginsenoside Rg1 against Hyperphosphorylated Tau-Induced Diabetic Retinal Neurodegeneration via Activation of IRS-1/Akt/GSK3β Signaling.

Journal of agricultural and food chemistry·2019

Same author

Evaluation of dynamic stereopsis in intermittent exotropia patients.

International journal of ophthalmology·2019

Same author

Efficacy of autologous conjunctival flap on repairing the late-onset filtering bleb leakage.

International journal of ophthalmology·2018

Same author

Longitudinal Cohort Study on the Incidence of Primary Open-Angle Glaucoma in Bai Chinese.

American journal of ophthalmology·2017

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

[Progress of anti-glaucoma fixed combination formulation].

Yang-Fan Yang¹, Min-Bin Yu

¹State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China.

[Zhonghua Yan Ke Za Zhi] Chinese Journal of Ophthalmology

|March 24, 2011

Summary

This summary is machine-generated.

Fixed combination eye drops offer a safer, more effective, and compliant treatment for glaucoma patients, improving intraocular pressure control compared to traditional therapies.

Related Experiment Videos

Last Updated: Jun 3, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

Ophthalmology
Pharmacology

Context:

Glaucoma is a leading cause of irreversible blindness.
Effective intraocular pressure (IOP) control is crucial for managing glaucoma, particularly primary open-angle glaucoma.
Single-drug therapies often fail to achieve target IOP in patients with high baseline pressures.

Purpose:

To review comparative studies on the therapeutic effects of fixed-combination anti-glaucoma formulations.
To summarize the characteristics of various fixed-combination glaucoma medications.
To discuss future trends in anti-glaucoma drug development.

Summary:

Traditional unfixed combination glaucoma therapy presents challenges including increased dosing frequency, reduced patient compliance, and higher preservative exposure.
New fixed-combination formulations have been developed to enhance safety, efficacy, and patient compliance in glaucoma management.
These novel formulations aim to provide more consistent IOP reduction and improve the daily lives of glaucoma patients.

Impact:

Fixed-combination therapies offer a more convenient and potentially more effective treatment option for glaucoma patients.
Improved compliance and sustained IOP control can help prevent further vision loss from glaucoma.
Advancements in fixed-combination formulations represent a significant step forward in managing this sight-threatening condition.